Next Article in Journal
Rewarming Injury after Cold Preservation
Next Article in Special Issue
Roles of Natural Killer T Cells and Natural Killer Cells in Kidney Injury
Previous Article in Journal
Straightforward Protein-Protein Interaction Interface Mapping via Random Mutagenesis and Mammalian Protein Protein Interaction Trap (MAPPIT)
Previous Article in Special Issue
Cytotoxicity of Human Hepatic Intrasinusoidal CD56bright Natural Killer Cells against Hepatocellular Carcinoma Cells
Review

Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(9), 2057; https://doi.org/10.3390/ijms20092057
Received: 5 April 2019 / Revised: 21 April 2019 / Accepted: 23 April 2019 / Published: 26 April 2019
(This article belongs to the Special Issue Natural Killer and NKT Cells)
The most common cause of death in patients with acute myeloid leukemia (AML) who receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) is AML relapse. Therefore, additive therapies post allo-HSCT have significant potential to prevent relapse. Natural killer (NK)-cell-based immunotherapies can be incorporated into the therapeutic armamentarium for the eradication of AML cells post allo-HSCT. In recent studies, NK cell-based immunotherapies, the use of adoptive NK cells, NK cells in combination with cytokines, immune checkpoint inhibitors, bispecific and trispecific killer cell engagers, and chimeric antigen receptor-engineered NK cells have all shown antitumor activity in AML patients. In this review, we will discuss the current strategies with these NK cell-based immunotherapies as possible therapies to cure AML patients post allo-HSCT. Additionally, we will discuss various means of immune escape in order to further understand the mechanism of NK cell-based immunotherapies against AML. View Full-Text
Keywords: natural killer cell; immunotherapy; allogeneic hematopoietic stem cell transplantation; acute myeloid leukemia; immune checkpoint; bispecific and trispecific killer cell engagers; chimeric antigen receptors natural killer cell; immunotherapy; allogeneic hematopoietic stem cell transplantation; acute myeloid leukemia; immune checkpoint; bispecific and trispecific killer cell engagers; chimeric antigen receptors
Show Figures

Graphical abstract

MDPI and ACS Style

Hattori, N.; Nakamaki, T. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Int. J. Mol. Sci. 2019, 20, 2057. https://doi.org/10.3390/ijms20092057

AMA Style

Hattori N, Nakamaki T. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. International Journal of Molecular Sciences. 2019; 20(9):2057. https://doi.org/10.3390/ijms20092057

Chicago/Turabian Style

Hattori, Norimichi, and Tsuyoshi Nakamaki. 2019. "Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia" International Journal of Molecular Sciences 20, no. 9: 2057. https://doi.org/10.3390/ijms20092057

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop